

## Branded VASCEPA® (icosapent ethyl) is now covered by major national PBMs and health plans on formulary:

- ▶ With a generic copay
- ▶ With no prior authorizations or other restrictions
- ▶ For 50 million lives in the Commercial business segment\*

### FORMULARY STATUS FOR SELECT PLANS

Plan name	Business segment	Formulary status
CVS Caremark	Commercial	Generic copay, Unrestricted
Aetna	Commercial	Generic copay, Unrestricted
MedImpact	Commercial	Generic copay, Unrestricted
Elixir	Commercial	Generic copay, Unrestricted
Navitus	Commercial	Generic copay, Unrestricted

Even patients paying a generic copay may have their copay reduced by using the VASCEPA Savings Card.

Contact your Amarin Sales Professional for plans in your area

**Commercially insured patients can pay as little as \$9 for a 90-day<sup>†</sup> supply with the VASCEPA Savings Card. Subject to eligibility. Restrictions apply.<sup>†</sup>**

**You can download the universal VASCEPA Savings Card<sup>‡</sup> at [vascepahcp.com/savings](http://vascepahcp.com/savings)**

Please ensure your patients receive branded VASCEPA. Write VASCEPA marked as "Dispense as written (DAW)" or "Brand medically necessary."



Unrestricted: No preset requirements or criteria must be met prior to filling a script on an unrestricted formulary. (No barriers to access apply.)

Prior authorization (PA): Implies a required criteria must be met by the patient in order to receive VASCEPA.

Generic tier: Demonstrates a health plan makes VASCEPA available to its patients requiring only a generic tier copay.

\*Data on file.

<sup>†</sup>Offer Restrictions: May not be used to obtain prescription drugs paid in part by Federal or State Programs including Medicare, Medicaid, Medicare Advantage, Medicare Part D, Tricare, VA. Most eligible, insured patients will pay as little as \$9 of their copay for either each month or a 90 day fill, with a maximum savings of up to \$150 per month or \$450 on a 90 day fill. Not for use by residents of VT, nor medical professionals licensed in VT, or by residents or physicians in states where similar programs are prohibited by law. This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay card. Void where prohibited by law, taxed, or restricted. Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash. Offer good through December 31, 2021.

<sup>‡</sup>Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes.

### INDICATIONS AND LIMITATIONS OF USE

- VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels ( $\geq 150$  mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
- VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe ( $\geq 500$  mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

### IMPORTANT SAFETY INFORMATION

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

**Please see additional Important Safety Information for VASCEPA on the next page. Please see accompanying full [Prescribing Information](#) for VASCEPA or go to [www.vascepahcp.com](http://www.vascepahcp.com).**

**Vascepa®**  
(icosapent ethyl)



## IMPORTANT SAFETY INFORMATION (cont'd)

- VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
- It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
- VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
- Common adverse reactions in the cardiovascular outcomes trial (incidence  $\geq 3\%$  and  $\geq 1\%$  more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
- Common adverse reactions in the hypertriglyceridemia trials (incidence  $\geq 1\%$  more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
- Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [AmarinConnect@Amarincorp.com](mailto:AmarinConnect@Amarincorp.com), or calling the FDA at 1-800-FDA-1088
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

**Please see additional Important Safety Information for VASCEPA on the previous page.**

**Please see accompanying full [Prescribing Information](#) for VASCEPA or go to [www.vascepahcp.com](http://www.vascepahcp.com).**

